

Luigi Tarantini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8416473/publications.pdf>

Version: 2024-02-01

87
papers

2,189
citations

257450
24
h-index

243625
44
g-index

101
all docs

101
docs citations

101
times ranked

3658
citing authors

#	ARTICLE	IF	CITATIONS
1	Cardio-Oncology in the COVID Era (Co & Co): The Never Ending Story. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 821193.	2.4	2
2	Trends in Incidence and Mortality of Kidney Cancer in a Northern Italian Province: An Update to 2020. <i>Biology</i> , 2022, 11, 1048.	2.8	1
3	Cancer in adult patients with inflammatory arthritis is associated with high ascending aortic stiffness and left ventricular hypertrophy and diastolic dysfunction. <i>Internal and Emergency Medicine</i> , 2021, 16, 73-81.	2.0	1
4	Clinical profile and outcome of patients with chronic inflammatory arthritis and metabolic syndrome. <i>Internal and Emergency Medicine</i> , 2021, 16, 863-874.	2.0	5
5	The troubling liaison between cancer and metabolic syndrome in chronic inflammatory rheumatic diseases. <i>Arthritis Research and Therapy</i> , 2021, 23, 89.	3.5	0
6	Adjuvant Hormonotherapy and Cardiovascular Risk in Post-Menopausal Women with Breast Cancer: A Large Population-Based Cohort Study. <i>Cancers</i> , 2021, 13, 2254.	3.7	9
7	Portrait of Italian Cardio-Oncology: Results of a Nationwide Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO) Survey. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 677544.	2.4	7
8	ANMCO POSITION PAPER: cardio-oncology in the COVID era (CO and CO). <i>European Heart Journal Supplements</i> , 2021, 23, C128-C153.	0.1	7
9	A Population-Based Study of Cardiovascular Disease Mortality in Italian Cancer Patients. <i>Cancers</i> , 2021, 13, 5903.	3.7	4
10	Cardiovascular Risk After Adjuvant Trastuzumab in Early Breast Cancer: An Italian Population-Based Cohort Study. <i>Oncologist</i> , 2020, 25, e1492-e1499.	3.7	5
11	Oncology and Cardiac Rehabilitation: An Underrated Relationship. <i>Journal of Clinical Medicine</i> , 2020, 9, 1810.	2.4	23
12	Cardio-oncology: the new frontier of clinical and preventive cardiology. <i>Monaldi Archives for Chest Disease</i> , 2020, 90, .	0.6	5
13	Long term follow-up (F/U) report of symptomatic cardiac events (SCEs) in 2,809 breast cancer (BC) patients (pts) treated with adjuvant trastuzumab (T) in real world (RW) practice. <i>Annals of Oncology</i> , 2019, 30, v718.	1.2	1
14	Cardiovascular Risk Factors and Timing of Anthracyclines and Trastuzumab Cardiac Toxicity. <i>Anticancer Research</i> , 2019, 39, 5741-5745.	1.1	9
15	An update on the conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting TKI-based therapy. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 485-496.	2.4	10
16	Are aortic coarctation and rheumatoid arthritis different models of aortic stiffness? Data from an echocardiographic study. <i>Cardiovascular Ultrasound</i> , 2018, 16, 9.	1.6	2
17	Prevalence and prognostic impact of non-cardiac co-morbidities in heart failure outpatients with preserved and reduced ejection fraction: a community-based study. <i>European Journal of Heart Failure</i> , 2018, 20, 1257-1266.	7.1	130
18	Cardiotoxicity of capecitabine: Captions not to bin. <i>International Journal of Cardiology</i> , 2017, 229, 6.	1.7	0

#	ARTICLE	IF	CITATIONS
19	ANMCO/AIOM/AICO Consensus Document on clinical and management pathways of cardio-oncology: executive summary. European Heart Journal Supplements, 2017, 19, D370-D379.	0.1	22
20	Cardiotoxicity of Aromatase Inhibitors in Breast Cancer Patients. Clinical Breast Cancer, 2017, 17, 11-17.	2.4	60
21	Progression of Renal Impairment and Chronic Kidney Disease in Chronic Heart Failure: An Analysis From GISSI-HF. Journal of Cardiac Failure, 2017, 23, 2-9.	1.7	26
22	Atrial fibrillation, cognitive impairment, frailty and disability in older heart failure patients. Journal of Cardiovascular Medicine, 2016, 17, 616-623.	1.5	20
23	Cardiac arrest and ventricular fibrillation in a young man treated with capecitabine: Case report and literature review. International Journal of Cardiology, 2016, 220, 280-283.	1.7	8
24	Insights from Cardiac Mechanics after Three Decades from Successfully Repaired Aortic Coarctation. Congenital Heart Disease, 2016, 11, 254-261.	0.2	4
25	Chronic kidney disease and prognosis in elderly patients with cardiovascular disease: Comparison between CKD-EPI and Berlin Initiative Study-1 formulas. European Journal of Preventive Cardiology, 2016, 23, 1504-1513.	1.8	10
26	Clinical profile and outcome of patients with rheumatoid arthritis and abnormally high aortic stiffness. European Journal of Preventive Cardiology, 2016, 23, 1848-1859.	1.8	16
27	Reasons why patients suffering from chronic heart failure at very low risk for mortality die. International Journal of Cardiology, 2016, 223, 947-952.	1.7	2
28	Incremental Value of Gait Speed in Predicting Prognosis of Older Adults With Heart Failure. JACC: Heart Failure, 2016, 4, 289-298.	4.1	93
29	Prognostic significance of anaemia in patients with heart failure with preserved and reduced ejection fraction: results from the MAGGIC individual patient data meta-analysis. QJM - Monthly Journal of the Association of Physicians, 2016, 109, 377-382.	0.5	28
30	Value of Combined Circumferential and Longitudinal Left Ventricular Systolic Dysfunction to Predict Adverse Outcome in Patients with Asymptomatic Aortic Stenosis. Journal of Heart Valve Disease, 2016, 25, 28-38.	0.5	3
31	Echocardiographic markers of inducible myocardial ischemia at baseline evaluation preparatory to exercise stress echocardiography. Cardiovascular Ultrasound, 2015, 14, 21.	1.6	0
32	Analysis of Left Atrial Performance in Patients with Type 2 Diabetes Mellitus without Overt Cardiac Disease and Inducible Ischemia: High Prevalence of Increased Systolic Force Related to Enhanced Left Ventricular Systolic Longitudinal Function. Echocardiography, 2015, 32, 221-228.	0.9	1
33	Combined Circumferential and Longitudinal Left Ventricular Systolic Dysfunction in Patients with Asymptomatic Aortic Stenosis. Echocardiography, 2015, 32, 1064-1072.	0.9	8
34	Left ventricular systolic dysfunction in chronic kidney disease: from asymptomatic changes in geometry and function to overt heart failure. Monaldi Archives for Chest Disease, 2015, 82, 10-5.	0.6	0
35	Role of a multidisciplinary program in improving outcomes in cognitively impaired heart failure older patients. Monaldi Archives for Chest Disease, 2015, 78, 20-8.	0.6	7
36	Does metabolic syndrome worsen systolic dysfunction in diabetes? The shortwave study. Acta Diabetologica, 2015, 52, 143-151.	2.5	4

#	ARTICLE	IF	CITATIONS
37	Does treatment assignment influence the prognosis of patients with symptomatic severe aortic stenosis?. Cardiovascular Ultrasound, 2015, 13, 2.	1.6	2
38	Clinical implications of the CKD epidemiology collaboration (CKD-EPI) equation compared with the modification of diet in renal disease (MDRD) study equation for the estimation of renal dysfunction in patients with cardiovascular disease. Internal and Emergency Medicine, 2015, 10, 955-963.	2.0	13
39	Does renal function influence the prognostic impact of type 2 diabetes mellitus in patients with chronic heart failure and left ventricular dysfunction?. IJC Metabolic & Endocrine, 2014, 4, 53-57.	0.5	0
40	Left Atrial Work in Patients with Stable Chronic Heart Failure: Factors Associated and Prognostic Role. Echocardiography, 2014, 31, 123-132.	0.9	19
41	Chronic renal dysfunction and anaemia are associated with cognitive impairment in older patients with heart failure. Journal of Cardiovascular Medicine, 2014, 15, 481-490.	1.5	29
42	Role of hypertension on new onset congestive heart failure in patients receiving trastuzumab therapy for breast cancer. Journal of Cardiovascular Medicine, 2014, 15, 141-146.	1.5	23
43	Reasons why patients suffering from chronic heart failure at very high risk for death survive. International Journal of Cardiology, 2014, 177, 213-218.	1.7	3
44	Cardiovascular risk stratification and management of patients with rheumatoid arthritis in clinical practice: The "EPIDAURO registry". International Journal of Cardiology, 2014, 172, 534-536.	1.7	10
45	Heart failure in younger patients: the Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). European Heart Journal, 2014, 35, 2714-2721.	2.2	71
46	LDL cholesterol levels in patients with coronary artery disease in real word: data from Cardiovascular Registry of Trieste. Cardiologia Croatica, 2014, 9, 247-247.	0.0	0
47	Is it time to calculate renal function in non valvular atrial fibrillation patients to stratify the risk of future events?. Cardiologia Croatica, 2014, 9, 210-210.	0.0	0
48	Prognostic impact of CHA2DS2VASC and renal dysfunction in non valvular atrial fibrillation patients: which is the best equation to stratify risk of future events?. Cardiologia Croatica, 2014, 9, 204-204.	0.0	0
49	The increasing detection of asymptomatic left ventricular dysfunction in patients with type 2 diabetes mellitus without overt cardiac disease: Data from the SHORTWAVE study. Diabetes Research and Clinical Practice, 2013, 101, 309-316.	2.8	72
50	Clinical features, and in-hospital and 1-year mortalities of patients with acute heart failure and severe renal dysfunction. Data from the Italian Registry IN-HF Outcome. International Journal of Cardiology, 2013, 168, 3691-3697.	1.7	20
51	Severe aortic valve stenosis with normal left ventricular function and low vs. high pressure gradient: Different hemodynamic profiles but similar clinical presentation, comorbidity and outcome. International Journal of Cardiology, 2013, 167, 2326-2328.	1.7	7
52	The worrisome liaison between left ventricular systolic dysfunction and mitral annulus calcification in type 2 diabetes without coronary artery disease: Data from the SHORTWAVE study. Nutrition, Metabolism and Cardiovascular Diseases, 2013, 23, 1188-1194.	2.6	5
53	Prognostic Stratification by Conventional Echocardiography of Patients with Aortic Stenosis: The "CAIMAN" ECHO Score. Echocardiography, 2013, 30, 367-377.	0.9	12
54	Prevalence and prognostic role of anaemia in patients with acute heart failure and preserved or depressed ventricular function. Internal and Emergency Medicine, 2013, 8, 147-155.	2.0	18

#	ARTICLE	IF	CITATIONS
55	Cardiovascular Biomarkers, Cardiac Dysfunction, and Outcomes in Patients With Type 2 Diabetes: A Prospective, Multicenter Study. <i>Diabetes Care</i> , 2013, 36, e137-e138.	8.6	3
56	Evaluation of different strategies for identifying asymptomatic left ventricular dysfunction and preclinical (stage B) heart failure in the elderly. Results from the PREDICTOR™, a population based study in central Italy. <i>European Journal of Heart Failure</i> , 2013, 15, 1102-1112.	7.1	25
57	Utility of 2D-speckle tracking echocardiography in early identification of left ventricular dysfunction in antineoplastic therapy-induced cardiotoxicity.. <i>Journal of Clinical Oncology</i> , 2013, 31, 631-631.	1.6	10
58	Role of hypertension on new onset congestive heart failure in patients receiving trastuzumab adjuvant chemotherapy for early breast cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, e11556-e11556.	1.6	0
59	Combined circumferential and longitudinal left ventricular systolic dysfunction in patients with type 2 diabetes mellitus without myocardial ischemia. <i>Experimental and Clinical Cardiology</i> , 2013, 18, e26-31.	1.3	8
60	Adjuvant trastuzumab cardiotoxicity in patients over 60 years of age with early breast cancer: a multicenter cohort analysis. <i>Annals of Oncology</i> , 2012, 23, 3058-3063.	1.2	55
61	Renal Dysfunction in Patients With Heart Failure With Preserved Versus Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2012, 5, 309-314.	3.9	152
62	Analysis of midwall shortening reveals high prevalence of left ventricular myocardial dysfunction in patients with diabetes mellitus: the DYDA study. <i>European Journal of Preventive Cardiology</i> , 2012, 19, 935-943.	1.8	28
63	Administration of Angiotensin-Converting Enzyme Inhibitors and β -Blockers During Adjuvant Trastuzumab Chemotherapy for Nonmetastatic Breast Cancer: Marker of Risk or Cardioprotection in the Real World?. <i>Oncologist</i> , 2012, 17, 917-924.	3.7	44
64	Trastuzumab Adjuvant Chemotherapy and Cardiotoxicity in Real-World Women With Breast Cancer. <i>Journal of Cardiac Failure</i> , 2012, 18, 113-119.	1.7	91
65	Role of renal function on the development of cardiotoxicity associated with trastuzumab-based adjuvant chemotherapy for early breast cancer. <i>Internal and Emergency Medicine</i> , 2012, 7, 439-446.	2.0	45
66	Analysis of Circumferential and Longitudinal Left Ventricular Systolic Function in Patients With Non-Ischemic Chronic Heart Failure and Preserved Ejection Fraction (from the CARRY-IN-HFpEF Study). <i>American Journal of Cardiology</i> , 2012, 109, 383-389.	1.6	34
67	Relationship between changes in left ventricular ejection and use of angiotensin-converting enzyme inhibitors and/or betablockers during adjuvant trastuzumab chemotherapy in early breast cancer: Data from the real world.. <i>Journal of Clinical Oncology</i> , 2012, 30, 645-645.	1.6	0
68	Prognostic effect of inappropriately high left ventricular mass in asymptomatic severe aortic stenosis. <i>Heart</i> , 2011, 97, 301-307.	2.9	243
69	Inappropriately high left ventricular mass in patients with type 2 diabetes mellitus and no overt cardiac disease. The DYDA study. <i>Journal of Hypertension</i> , 2011, 29, 1994-2003.	0.5	17
70	Chronic kidney disease elicits excessive increase in left ventricular mass growth in patients at increased risk for cardiovascular events. <i>Journal of Hypertension</i> , 2011, 29, 565-573.	0.5	53
71	Predictors of early-stage left ventricular dysfunction in type 2 diabetes: results of DYDA study. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2011, 18, 415-423.	2.8	28
72	Usefulness of frailty profile for targeting older heart failure patients in disease management programs: a cost-effectiveness, pilot study. <i>Journal of Cardiovascular Medicine</i> , 2010, 11, 739-747.	1.5	87

#	ARTICLE	IF	CITATIONS
73	Translation and validation of the Italian version of the European Heart Failure Self-care Behaviour Scale. <i>Journal of Cardiovascular Medicine</i> , 2010, 11, 493-498.	1.5	19
74	Evolution of renal function during and after an episode of cardiac decompensation: results from the Italian survey on acute heart failure. <i>Journal of Cardiovascular Medicine</i> , 2010, 11, 234-243.	1.5	18
75	Left atrial size and force in patients with systolic chronic heart failure: Comparison with healthy controls and different cardiac diseases. <i>Experimental and Clinical Cardiology</i> , 2010, 15, e45-51.	1.3	14
76	Right atrial size and function in patients with pulmonary hypertension associated with disorders of respiratory system or hypoxemia. <i>European Journal of Echocardiography</i> , 2007, 8, 322-331.	2.3	81
77	Prevalence, predictors and prognostic value of acute impairment in renal function during intensive unloading therapy in a community population hospitalized for decompensated heart failure. <i>Journal of Cardiovascular Medicine</i> , 2007, 8, 419-427.	1.5	25
78	Safety and efficacy of carvedilol in very elderly diabetic patients with heart failure. <i>Journal of Cardiovascular Medicine</i> , 2007, 8, 675-682.	1.5	9
79	Changes in Plasma N-Terminal proBNP Levels and Ventricular Filling Pressures During Intensive Unloading Therapy in Elderly With Decompensated Congestive Heart Failure and Preserved Left Ventricular Systolic Function. <i>Journal of Cardiac Failure</i> , 2006, 12, 608-615.	1.7	23
80	Does atrial fibrillation in very elderly patients with chronic systolic heart failure limit the use of carvedilol?. <i>International Journal of Cardiology</i> , 2006, 107, 220-224.	1.7	9
81	Pharmacological left ventricular reverse remodeling in elderly patients receiving optimal therapy for chronic heart failure. <i>European Journal of Heart Failure</i> , 2005, 7, 1040-1048.	7.1	15
82	Functional mitral regurgitation predicts 1-year mortality in elderly patients with systolic chronic heart failure. <i>European Journal of Heart Failure</i> , 2005, 7, 1112-1117.	7.1	84
83	Chronic left ventricular failure in the community: prevalence, prognosis, and predictors of the complete clinical recovery with return of cardiac size and function to normal in patients undergoing optimal therapy. <i>Journal of Cardiac Failure</i> , 2004, 10, 250-257.	1.7	30
84	Dilated versus nondilated cardiomyopathy in the elderly population treated with guideline-based medical therapy for systolic chronic heart failure. <i>Journal of Cardiac Failure</i> , 2004, 10, 481-489.	1.7	9
85	Hemodynamic response to intensive unloading therapy (furosemide and nitroprusside) in patients >70 years of age with left ventricular systolic dysfunction and decompensated chronic heart failure. <i>American Journal of Cardiology</i> , 2003, 92, 1050-1056.	1.6	20
86	Prevalence, predictors, and prognostic implications of improvement in left ventricular systolic function and clinical status in patients >70 years of age with recently diagnosed systolic heart failure. <i>American Journal of Cardiology</i> , 2003, 92, 166-172.	1.6	31
87	Prescription patterns of diuretics in chronic heart failure: A contemporary background as a clue to their role in treatment. <i>Journal of Cardiac Failure</i> , 2003, 9, 210-218.	1.7	25